A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control

Jennifer D. Stone, Daniel T. Harris, Carolina M. Soto, Adam S. Chervin, David H. Aggen, Edward J Roy, David M Kranz

Research output: Contribution to journalArticle

Abstract

Adoptive transfer of genetically modified T cells to treat cancer has shown promise in several clinical trials. Two main strategies have been applied to redirect T cells against cancer: (1) introduction of a full-length T cell receptor (TCR) specific for a tumor-associated peptide—MHC, or (2) introduction of a chimeric antigen receptor, including an antibody fragment specific for a tumor cell surface antigen, linked intracellularly to T cell signaling domains. Each strategy has advantages and disadvantages for clinical applications. Here, we present data on the in vitro and in vivo effectiveness of a single-chain signaling receptor incorporating a TCR variable fragment as the targeting element (referred to as TCR-SCS). This receptor contained a single-chain TCR (Vα-linker-Vβ) from a high-affinity TCR called m33, linked to the intracellular signaling domains of CD28 and CD3ζ. This format avoided mispairing with endogenous TCR chains and mediated specific T cell activity when expressed in either CD4 or CD8 T cells. TCR-SCS-transduced CD8-negative cells showed an intriguing sensitivity, compared to full-length TCRs, to higher densities of less stable pepMHC targets. T cells that expressed this peptide-specific receptor persisted in vivo, and exhibited polyfunctional responses. Growth of metastatic antigen-positive tumors was significantly inhibited by T cells that expressed this receptor, and tumor cells that escaped were antigen-loss variants. TCR-SCS receptors represent an alternative targeting receptor strategy that combines the advantages of single-chain expression, avoidance of TCR chain mispairing, and targeting of intracellular antigens presented in complex with MHC proteins.

Original languageEnglish (US)
Pages (from-to)1163-1176
Number of pages14
JournalCancer Immunology, Immunotherapy
Volume63
Issue number11
DOIs
StatePublished - Jan 1 2014

Fingerprint

T-Cell Antigen Receptor
T-Lymphocytes
Antigens
Neoplasms
Immunoglobulin Fragments
Antigen Receptors
Peptide Receptors
Adoptive Transfer
Neoplasm Antigens
Surface Antigens
Clinical Trials
Growth

Keywords

  • Adoptive T cell transfer
  • Chimeric antigen receptors
  • Melanoma
  • T cell receptors
  • Tumor targeting

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. / Stone, Jennifer D.; Harris, Daniel T.; Soto, Carolina M.; Chervin, Adam S.; Aggen, David H.; Roy, Edward J; Kranz, David M.

In: Cancer Immunology, Immunotherapy, Vol. 63, No. 11, 01.01.2014, p. 1163-1176.

Research output: Contribution to journalArticle

Stone, Jennifer D. ; Harris, Daniel T. ; Soto, Carolina M. ; Chervin, Adam S. ; Aggen, David H. ; Roy, Edward J ; Kranz, David M. / A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. In: Cancer Immunology, Immunotherapy. 2014 ; Vol. 63, No. 11. pp. 1163-1176.
@article{9142f83ba996474d9038893de50dc29f,
title = "A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control",
abstract = "Adoptive transfer of genetically modified T cells to treat cancer has shown promise in several clinical trials. Two main strategies have been applied to redirect T cells against cancer: (1) introduction of a full-length T cell receptor (TCR) specific for a tumor-associated peptide—MHC, or (2) introduction of a chimeric antigen receptor, including an antibody fragment specific for a tumor cell surface antigen, linked intracellularly to T cell signaling domains. Each strategy has advantages and disadvantages for clinical applications. Here, we present data on the in vitro and in vivo effectiveness of a single-chain signaling receptor incorporating a TCR variable fragment as the targeting element (referred to as TCR-SCS). This receptor contained a single-chain TCR (Vα-linker-Vβ) from a high-affinity TCR called m33, linked to the intracellular signaling domains of CD28 and CD3ζ. This format avoided mispairing with endogenous TCR chains and mediated specific T cell activity when expressed in either CD4 or CD8 T cells. TCR-SCS-transduced CD8-negative cells showed an intriguing sensitivity, compared to full-length TCRs, to higher densities of less stable pepMHC targets. T cells that expressed this peptide-specific receptor persisted in vivo, and exhibited polyfunctional responses. Growth of metastatic antigen-positive tumors was significantly inhibited by T cells that expressed this receptor, and tumor cells that escaped were antigen-loss variants. TCR-SCS receptors represent an alternative targeting receptor strategy that combines the advantages of single-chain expression, avoidance of TCR chain mispairing, and targeting of intracellular antigens presented in complex with MHC proteins.",
keywords = "Adoptive T cell transfer, Chimeric antigen receptors, Melanoma, T cell receptors, Tumor targeting",
author = "Stone, {Jennifer D.} and Harris, {Daniel T.} and Soto, {Carolina M.} and Chervin, {Adam S.} and Aggen, {David H.} and Roy, {Edward J} and Kranz, {David M}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00262-014-1586-z",
language = "English (US)",
volume = "63",
pages = "1163--1176",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "11",

}

TY - JOUR

T1 - A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control

AU - Stone, Jennifer D.

AU - Harris, Daniel T.

AU - Soto, Carolina M.

AU - Chervin, Adam S.

AU - Aggen, David H.

AU - Roy, Edward J

AU - Kranz, David M

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Adoptive transfer of genetically modified T cells to treat cancer has shown promise in several clinical trials. Two main strategies have been applied to redirect T cells against cancer: (1) introduction of a full-length T cell receptor (TCR) specific for a tumor-associated peptide—MHC, or (2) introduction of a chimeric antigen receptor, including an antibody fragment specific for a tumor cell surface antigen, linked intracellularly to T cell signaling domains. Each strategy has advantages and disadvantages for clinical applications. Here, we present data on the in vitro and in vivo effectiveness of a single-chain signaling receptor incorporating a TCR variable fragment as the targeting element (referred to as TCR-SCS). This receptor contained a single-chain TCR (Vα-linker-Vβ) from a high-affinity TCR called m33, linked to the intracellular signaling domains of CD28 and CD3ζ. This format avoided mispairing with endogenous TCR chains and mediated specific T cell activity when expressed in either CD4 or CD8 T cells. TCR-SCS-transduced CD8-negative cells showed an intriguing sensitivity, compared to full-length TCRs, to higher densities of less stable pepMHC targets. T cells that expressed this peptide-specific receptor persisted in vivo, and exhibited polyfunctional responses. Growth of metastatic antigen-positive tumors was significantly inhibited by T cells that expressed this receptor, and tumor cells that escaped were antigen-loss variants. TCR-SCS receptors represent an alternative targeting receptor strategy that combines the advantages of single-chain expression, avoidance of TCR chain mispairing, and targeting of intracellular antigens presented in complex with MHC proteins.

AB - Adoptive transfer of genetically modified T cells to treat cancer has shown promise in several clinical trials. Two main strategies have been applied to redirect T cells against cancer: (1) introduction of a full-length T cell receptor (TCR) specific for a tumor-associated peptide—MHC, or (2) introduction of a chimeric antigen receptor, including an antibody fragment specific for a tumor cell surface antigen, linked intracellularly to T cell signaling domains. Each strategy has advantages and disadvantages for clinical applications. Here, we present data on the in vitro and in vivo effectiveness of a single-chain signaling receptor incorporating a TCR variable fragment as the targeting element (referred to as TCR-SCS). This receptor contained a single-chain TCR (Vα-linker-Vβ) from a high-affinity TCR called m33, linked to the intracellular signaling domains of CD28 and CD3ζ. This format avoided mispairing with endogenous TCR chains and mediated specific T cell activity when expressed in either CD4 or CD8 T cells. TCR-SCS-transduced CD8-negative cells showed an intriguing sensitivity, compared to full-length TCRs, to higher densities of less stable pepMHC targets. T cells that expressed this peptide-specific receptor persisted in vivo, and exhibited polyfunctional responses. Growth of metastatic antigen-positive tumors was significantly inhibited by T cells that expressed this receptor, and tumor cells that escaped were antigen-loss variants. TCR-SCS receptors represent an alternative targeting receptor strategy that combines the advantages of single-chain expression, avoidance of TCR chain mispairing, and targeting of intracellular antigens presented in complex with MHC proteins.

KW - Adoptive T cell transfer

KW - Chimeric antigen receptors

KW - Melanoma

KW - T cell receptors

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=84939886228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939886228&partnerID=8YFLogxK

U2 - 10.1007/s00262-014-1586-z

DO - 10.1007/s00262-014-1586-z

M3 - Article

C2 - 25082071

AN - SCOPUS:84939886228

VL - 63

SP - 1163

EP - 1176

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 11

ER -